Bacteria in the gut could stimulate tumor cells to produce factors that regulate cell mobility called chemokines that recruit T cells to the tumor, which is linked to improved outcomes, according to data presented at the ...
Sep 6, 2017
0
3
Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival was associated with the patient's immune status, according ...
Sep 6, 2017
0
0
Adipose tissue, or fat, may influence the development of cancer in diverse ways, depending on the type of fat and the location in the body.
Sep 1, 2017
0
2
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.
Aug 28, 2017
0
0
Bottom Line: In Texas, the average cost for the first two years of health care after a diagnosis of oropharyngeal cancer was $139,749.
Aug 24, 2017
0
1
Bottom Line: Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7 percent of patients with carcinoma of unknown primary (CUP) who ...
Aug 15, 2017
0
3
Whole genome sequencing using long fragment read (LFR), a technology that can analyze the entire genomic content of small numbers of cells, detected potentially targetable mutations using only five circulating tumor cells ...
Aug 15, 2017
0
2
Two de-identification methods, k-anonymization and adding a "fuzzy factor," significantly reduced the risk of re-identification of patients in a dataset of 5 million patient records from a large cervical cancer screening ...
Jul 28, 2017
0
0
Molecular classification of the four distinct subtypes of gastric cancer could potentially shape tailored treatment options by helping to predict survival outcomes and patients' response to chemotherapy.
Jul 26, 2017
0
0
In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain ...
Jul 21, 2017
0
0
